October 07, 2005 13:45 ET

Routine Screening for Second-Hand Smoke Exposure Recommended; Nymox TobacAlert Product Detects Second-Hand Smoke Exposure

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 7, 2005) -

Routine screening and counseling of patients for second hand smoke exposure is part of a proposed guideline for preventing and reducing the deleterious health effects of such exposure (Families, Systems & Health 2005; 3:266-277). Pointing to the wealth of studies showing health risks posed by second hand smoke exposure, the authors, Dr. Geoffrey Williams, Dr Stephen Williams and Dr. Roy Kohn, recommend that second hand smoke exposure be approached in the same manner as tobacco product use, with physicians routinely screening patients for exposure followed by counseling about reducing or preventing exposure.

Nymox Pharmaceutical (NASDAQ:NYMX) makes TobacAlert™, an easy-to-use, cost-effective product that allows for on-site testing for second-hand smoke exposure. TobacAlert™ can be used at home, at school or in the workplace. No instruments are required and results are provided within minutes.

Second hand smoke exposure is increasingly recognized as a major public health risk, particularly for children, pregnant women and people with asthma or heart disease. Second hand smoke has been linked to increased risk of respiratory problems, lung, breast and other cancers, heart disease, and poor pregnancy outcomes and is classified as a class A carcinogen (the most serious category) by the U.S. Environmental Protection Agency. According to the California Air Resources Board, an estimated 50,000 deaths occur from second hand smoke exposure in the U.S. alone.

TobacAlert™ is available at over 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX